Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid : The PREDIABOLE study, a randomized controlled trial
© 2019 John Wiley & Sons Ltd..
AIM: To assess whether the regular intake of an oleanolic acid (OA)-enriched olive oil is effective in the prevention of diabetes.
METHODS: In the PREDIABOLE study, prediabetic individuals (impaired fasting glucose and impaired glucose tolerance) of both sexes (176 patients, aged 30-80 years) were randomized to receive 55 mL/day of OA-enriched olive oil (equivalent dose 30 mg OA/day) [intervention group (IG)] or the same oil not enriched [control group (CG)]. The main outcome was the incidence of new-onset type 2 diabetes in both groups.
RESULTS: Forty-eight new diabetes cases occurred, 31 in the CG and 17 in the IG. The multivariate-adjusted hazard ratio was 0.45 (95% CI, 0.24-0.83) for the IG compared with the CG. Intervention-related adverse effects were not reported.
CONCLUSIONS: The intake of OA-enriched olive oil reduces the risk of developing diabetes in prediabetic patients. The results of the PREDIABOLE study promote the use of OA in new functional foods and drugs for the prevention of diabetes in individuals at risk of developing it.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Diabetes, obesity & metabolism - 21(2019), 11 vom: 15. Nov., Seite 2526-2534 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Santos-Lozano, José M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.09.2020 Date Revised 28.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dom.13838 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299757587 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299757587 | ||
| 003 | DE-627 | ||
| 005 | 20231225101035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dom.13838 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0999.xml |
| 035 | |a (DE-627)NLM299757587 | ||
| 035 | |a (NLM)31364228 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santos-Lozano, José M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid |b The PREDIABOLE study, a randomized controlled trial |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.09.2020 | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 John Wiley & Sons Ltd. | ||
| 520 | |a AIM: To assess whether the regular intake of an oleanolic acid (OA)-enriched olive oil is effective in the prevention of diabetes | ||
| 520 | |a METHODS: In the PREDIABOLE study, prediabetic individuals (impaired fasting glucose and impaired glucose tolerance) of both sexes (176 patients, aged 30-80 years) were randomized to receive 55 mL/day of OA-enriched olive oil (equivalent dose 30 mg OA/day) [intervention group (IG)] or the same oil not enriched [control group (CG)]. The main outcome was the incidence of new-onset type 2 diabetes in both groups | ||
| 520 | |a RESULTS: Forty-eight new diabetes cases occurred, 31 in the CG and 17 in the IG. The multivariate-adjusted hazard ratio was 0.45 (95% CI, 0.24-0.83) for the IG compared with the CG. Intervention-related adverse effects were not reported | ||
| 520 | |a CONCLUSIONS: The intake of OA-enriched olive oil reduces the risk of developing diabetes in prediabetic patients. The results of the PREDIABOLE study promote the use of OA in new functional foods and drugs for the prevention of diabetes in individuals at risk of developing it | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a antidiabetic drug | |
| 650 | 4 | |a oleanolic acid | |
| 650 | 4 | |a phase I-II study | |
| 650 | 4 | |a primary care | |
| 650 | 4 | |a randomized trial | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 650 | 7 | |a Olive Oil |2 NLM | |
| 650 | 7 | |a Oleanolic Acid |2 NLM | |
| 650 | 7 | |a 6SMK8R7TGJ |2 NLM | |
| 700 | 1 | |a Rada, Mirela |e verfasserin |4 aut | |
| 700 | 1 | |a Lapetra, José |e verfasserin |4 aut | |
| 700 | 1 | |a Guinda, Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Rodríguez, María C |e verfasserin |4 aut | |
| 700 | 1 | |a Cayuela, José A |e verfasserin |4 aut | |
| 700 | 1 | |a Ángel-Lugo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Vilches-Arenas, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Martín, Ana M |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega-Calvo, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Castellano, José M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, obesity & metabolism |d 1999 |g 21(2019), 11 vom: 15. Nov., Seite 2526-2534 |w (DE-627)NLM111220432 |x 1463-1326 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2019 |g number:11 |g day:15 |g month:11 |g pages:2526-2534 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dom.13838 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2019 |e 11 |b 15 |c 11 |h 2526-2534 | ||